Intrinsic Medicine, Inc. (INRX)
| Market Cap | 67.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.95M |
| Shares Out | 11.29M |
| EPS (ttm) | -1.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About INRX
Intrinsic Medicine is a preclinical-stage therapeutics company leveraging synthetic biology-manufactured human identical milk oligosaccharide, or HiMO, molecules as new medicines to treat large patient populations underserved by current treatment options. In the first half of 2023, we plan to initiate a Phase 2 clinical trial under an approved protocol in Australia to test our lead drug candidate in over 400 patients with the constipation dominant form of irritable bowel syndrome, or IBS-C, which is estimated to affect approximately five millio...
Financial Performance
Financial StatementsNews
Inflammatory disease biotech Intrinsic Medicine files for a $29 million IPO
Intrinsic Medicine, a preclinical biotech developing HiMO therapies for GBA and inflammatory disorders, filed on Friday with the SEC to raise up to $29 million in an initial public offering.
Intrinsic Medicine IPO Registration Document (S-1)
Intrinsic Medicine has filed to go public with an IPO on the NASDAQ.